Vergleich

Recombinant Hepatitis B Virus Core Antigen (a.a. 184)

ArtNr DAG556
Hersteller Creative Diagnostics
Menge 100 ug
Kategorie
Typ Proteins Recombinant
Format Liquid
Applikationen ELISA
Specific against other
Purity ca.95%, pure (SDS-PAGE). Repetitive chromatography
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Lieferbar
Manufacturer - Applications
Suitable, for use in ELISA and Western blot. Each laboratory should determine an, optimum working titer for use in its particular application. Other, applications have not been tested but use in such assays should not necessarily, be excluded.
Storage Conditions
Aliquot, and store at -20°C. Avoid multiple freeze/thaw cycles.
Full name
Hepatitis B Virus Core Antigen
Product Overview
Recombinant, Hepatitis B Virus Core Antigen, full length core, protein(a.a 184), does not contain fusion partner, was, expressed in E. coli, and puried in vitro using conventional chromatography, techniques.
Background - Introduction
Hepatitis B virus, abbreviated HBV, is a species of the genus Orthohepadnavirus, which is, likewise a part of the Hepadnaviridae family of viruses. This virus causes, the disease hepatitis B.
Background - Keywords
Hepatitis B Core Ag, Hepatitis B Core Antigen, HBcAg, Hepatitis B Virus Core Antigen, Hepatitis B, virus, HBV, Core antigen, C, Capsid protein, Core protein, HBc, p21.5, Hepadnaviridae, Orthohepadnavirus
Abbr
HBcAg (a.a. 184)
Manufacturer - Format
Purified, Liquid
Buffer
50mM, Tris, 1mM EDTA, 150mM Sodium Chloride, pH 7.5
Concentration
0.85mg/ml, (OD280nm, E1% = 14)
Preservative
None
Antigen Description
Hepatitis B Virus, Core Antigen (HBcAg) is part of the infectious virion containing an inner, core particle enclosing the viral genome. The icosahedral core, particle contains 180 or 240 copies of the core protein. HBcAg is one of the, three major clinical antigens of hepatitis B virus but disappears early in, the course of infection. The hepatitis B virus core antigen (HBcAg) is a, highly immunogenic subviral particle and functions as both a T-cell-dependent, and a T-cell-independent antigen. Therefore, HBcAg may be a promising, candidate target for therapeutic vaccine control of chronic HBV infection.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen